Navigation Links
Video: Keppra XR(TM) Approved in the U.S.
Date:9/14/2008

- As adjunctive therapy Keppra XR(TM) offers significant partial onset

seizure reduction, proven tolerability, and once-daily dosing

- Keppra XR(TM) is built on a trusted heritage

ATLANTA, Sept. 15 /PRNewswire/ -- press release, regulated information: UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Keppra XR(TM) (levetiracetam extended-release tablets) for use as an add-on to other antiepileptic treatments for people with partial-onset seizures who are 16 years of age and older. Keppra XR(TM) is expected to be available in U.S. pharmacies at the end of September 2008.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/keppra/34625/

The goal of therapy with antiepileptic drugs (AED) is freedom from seizures and minimal side effects. While many people with epilepsy are successfully treated with one or more of the currently available antiepileptic drugs, a significant percentage still live with uncontrolled seizures or intolerable side effects.

"With solid clinical trial data supporting Keppra XR(TM) efficacy and tolerability, this once-daily antiepileptic drug can play an important role in treating people with epilepsy," said lead investigator Dr. Jukka Peltola, Department of Neurology, Tampere University Hospital, Finland. "We found in the clinical trial that Keppra XR(TM) provided significant partial onset seizure control in once-daily dosing when added to other antiepileptic drugs and that it was generally well-tolerated."

Building On A Trusted Heritage

"This is one of many milestones at UCB to develop new treatment options for people with epilepsy," said Troy Cox, Senior Vice President UCB & President CNS Operations. "Keppra XR(TM) provides a way to simplify treatment and offers another chance to achieve seizure control, which is an important goal for patie
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
2. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
3. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
4. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
5. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
6. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
7. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
8. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
9. US FDA Grants Pediatric Exclusivity for UCBs Keppra(R)
10. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)...ueen,s University Belfast are developing new senso...ch will help in the fight against the threat of te...gel pads to ,swipe, an individual or crime scene t...ning instrument that can detect the presence of ch...ster decisions to be made in response to terrorist...
(Date:11/18/2009)...nier,s experience in data analysis combined with B... kits and curricula provide state-of-the-art...ERTON, Ore., Nov. 18 Vernier Softw...ience interfaces, sensors, and software and Bio-Ra... and distributor of life science research and clin...
(Date:11/18/2009)...RINSTEAD, West Sussex, U.K. and CLEVELAND, Nov. 18...an Biosciences business and premier provider of di...icrobiology labs, has expanded its East Grinstead,...facility to meet increasing global demand for its ...nd identification testing. The expanded facility h...
(Date:11/18/2009)...AUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioS...ciences product development company that identifie...ncer-related products at various stages of develop...ng nimotuzumab were presented today in a poster at...cer Therapeutics conference in Boston, Massachuset...
Breaking Biology Technology:New technology detects chemical weapons in seconds 2Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education 2TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 2TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 3TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3
...aq: ENMD ) a clinical-stage pharmaceutical compan...cer and inflammatory diseases,announced today that...ident, Corporate and Business Development, will pr...tnering Europe Conference, which is being,held Oct...iss, presentation,is scheduled for Monday, October...
...Company,Limited ("Takeda") today announced that Ta... a wholly owned United States (U.S.) subsidiary,re...ministration (FDA) will,not be able to complete it...DA) by the Prescription Drug User Fee Act (PDUFA) ...cussion with the FDA, it indicated that due to,int...
...hesive got a new competitor this week with a stron...urnal Science by a team of researchers from four U...erested in the ability of gecko lizards to scurry ... creatures owe this amazing ability to microscopic...vantage of atomic-scale attractive forces to grip ...
Other Biology Technology:EntreMed to Present at BioPartnering Europe Conference 2EntreMed to Present at BioPartnering Europe Conference 3FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes 2Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability 2Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability 3Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability 4
(Date:11/20/2009)...m the production of flax shives, and generated fro...ated to those which engulf fields in spring, can b...ted by two studies carried out by Spanish and Dutc...ble and Sustainable Energy Reviews . , "These stu..., the production of bioethanol from two, as yet un...
(Date:11/20/2009)... a new study, researchers report that a class of h...elpful, or harmful, effect on the heart, depending... appears in the journal Circulation Research , fo... and beta-receptors on the heart muscle offer the ... target only the beta-receptors can actually under...
(Date:11/19/2009)...r ants, which cultivate fungus for food, have many...d to the list: the ant farmers, like their human c... make their gardens grow. The finding, reported th...nts a previously unknown symbiosis between ants an...er ants have come to dominate the American tropics...
Breaking Biology News(10 mins):Flax and yellow flowers can produce bioethanol 2Carvedilol shown to have unique characteristics among beta blockers 2Like humans, ants use bacteria to make their gardens grow 2Flu Shot Scheduling Chaos Cured by Appointment Plus Online Appointment Software 61051 1Flu Shot Scheduling Chaos Cured by Appointment Plus Online Appointment Software 61051 2Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 1Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 2Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 3Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 4Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 5Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 6Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 7Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 8Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 9Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 10Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 11Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 12Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 13Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 14Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 15Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 16Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 17Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 18Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 19Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 20Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 21Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 22Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 23Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 24Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 25Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 26Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 27Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 28Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 29Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 30Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 31Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 32Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of 240 61 Per Share and GAAP Earnings of 240 44 P 61047 33Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 6120 1Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 6120 2Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 6120 3Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 6120 4
... China and the United States have found evidence o...ssils from South China. The previous earliest evid...ed in Scotland. The discovery also adds to the sca...s about lichen evolution. , Xunlai Yuan, a paleont...Palaeontology; Shuhai Xiao, assistant professor of...
...lation within aircraft cabins can reduce the sprea...iew published in this week,s issue of THE LANCET. ...USA) and colleagues reviewed data from studies loo...cial air travel. They found that while commercial ... of pathogens carried by passengers or crew, the e...
...s study comparing strains of leprosy-causing bacte...ogen evolved and how it was spread across the cont...cientists at the Pasteur Institute in Paris, appea...lished by AAAS, the nonprofit science society. , ...prosy infections are all caused by a single bacter...
Other Biology News:Evidence of 600-million-year old fungi-algae symbiosis discovered in marine fossils 2Evidence of 600-million-year old fungi-algae symbiosis discovered in marine fossils 3Aircraft Cabin Ventilation Influences The Transmission Of Diseases In-flight 2Leprosy genome tells story of human migrations, French researchers report in Science 2Leprosy genome tells story of human migrations, French researchers report in Science 3
Mouse Anti-Kusabira Orange Monoclonal Antibody, Unconjugated, Clone 2G9 from MBL International
Anti-CD69 / CD3 Monoclonal Antibody, PE, PerCP Conjugated from BD Biosciences - Immunocytometry Systems
Rat Anti-Vitamin B3 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-CD18, phospho (Ser756 / Thr758 / Thr759) Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Biology Products: